Viking Therapeutics, Inc. filings document a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, and clinical-development disclosures for VK2735, including subcutaneous and oral obesity programs, trial results, and related regulatory communications.
The company's proxy materials disclose board and shareholder-voting matters, executive compensation, equity awards, and pay-versus-performance information. Viking's SEC record also covers Regulation FD communications, clinical-development updates, cash resources, and governance matters tied to a development-stage biotechnology issuer.
Viking Therapeutics, Inc. reported third-quarter 2026 financial results, including a net loss of $183.2 million, compared with $90.8 million a year earlier. Research and development expenses were $166.8 million and general and administrative expenses were $20.3 million, both higher than in the prior-year quarter. Cash, cash equivalents and short-term investments totaled $960 million at September 30, 2026, versus $706 million at December 31, 2025. Concurrent public offerings of common stock and convertible senior notes in September generated approximately $575 million in gross proceeds.
The subcutaneous VANQUISH trials continued, and Viking initiated the oral SUNRISE Phase 3 trials for VK2735; VANQUISH completion is expected in 2027. VANQUISH tests weekly injections over 78 weeks, while SUNRISE tests daily tablets over 68 weeks. In Part 1 of a maintenance study, mean weight loss retained at Week 33 was 83%–97% with every-other-week dosing and 82%–90% with monthly dosing. Part 2 began, with results expected in 2027. Viking expected to complete VK3019’s Phase 1 single-ascending-dose study later in the quarter and initiate a 4-week multiple-ascending-dose study in the first quarter of 2027.
Viking Therapeutics, Inc. (VKTX) completed an equity offering and a convertible debt offering on September 25, 2026. The equity offering comprised 7,857,143 common shares at $35.00 per share, plus 1,178,571 additional shares under an option exercised in full; net proceeds were approximately $297.0 million. The debt offering comprised $225,000,000 aggregate principal amount of 2.00% convertible senior notes due 2032, plus $33,750,000 under an option exercised in full; net proceeds were approximately $250.8 million.
The notes are senior, unsecured obligations, pay interest semi-annually beginning April 15, 2027, and mature October 15, 2032 unless earlier repurchased, redeemed or converted. Their initial conversion rate is 19.7044 common shares per $1,000 principal amount, representing an initial conversion price of approximately $50.75 per share. Viking may settle conversions in cash, shares or a combination, at its election. The company intends to use net proceeds from both offerings for continued clinical development, advancement and commercialization of VK2735; clinical development and advancement of VK3019; and other research and development, working capital and general corporate purposes.
Viking Therapeutics, Inc. is offering $225 million of 2.00% convertible senior notes due October 15, 2032, with an underwriters’ option to purchase up to an additional $33.75 million solely to cover over-allotments. Estimated net proceeds are $218.0 million, or $250.8 million if the option is exercised in full. Viking intends to use the proceeds for VK2735 clinical development, advancement and commercialization; VK3019 clinical development and advancement; and other research and development, working capital and general corporate purposes.
Separately, Viking is offering 7,857,143 common shares, plus an option for up to 1,178,571 shares; completion of either offering is not contingent on the other. The notes pay 2.00% annual interest semiannually beginning April 15, 2027. Their initial conversion rate is 19.7044 shares per $1,000 principal amount, equivalent to an approximately $50.75 conversion price; conversion is available only under specified conditions. In the VK2735 maintenance study, every-other-week dosing maintained up to 97% of mean weight loss from the weekly induction phase, versus 61% for placebo; monthly dosing maintained up to 90%, versus 61%.
Viking Therapeutics, Inc. (VKTX) is offering 7,857,143 common shares at $35.00 per share, with estimated net proceeds of approximately $258.2 million. Underwriters have a 30-day option to buy up to 1,178,571 additional shares; estimated net proceeds would be approximately $297.0 million if exercised in full. Viking intends to use proceeds for VK2735 and VK3019 development, research and development, working capital and general corporate purposes.
Separately, Viking is offering $225 million of 2.00% convertible senior notes due 2032, with an option for up to $33.75 million more. The note offering is not contingent on the stock offering; if completed, its estimated net proceeds are approximately $218.0 million.
In VK2735 maintenance-study results, after 21 weeks of weekly treatment and 12 weeks of maintenance dosing, every-other-week groups maintained up to 97% of mean weight loss achieved during induction, versus 61% for placebo; monthly groups maintained up to 90%, also versus 61%. During induction, weight loss ranged approximately 16% to 19%, compared with approximately 0% for placebo.
Viking Therapeutics, Inc. is offering convertible senior notes due October 15, 2032, alongside a separate common-stock offering; neither offering is contingent on the other. Noteholders may convert in specified circumstances, and Viking may elect to settle conversions in cash, common shares or a combination. Viking intends to use the note proceeds, together with proceeds from the stock offering if completed, for its VK2735 and VK3019 programs, other research and development, working capital and general corporate purposes.
The notes are senior unsecured obligations and structurally subordinated to subsidiary liabilities. As of June 30, 2026, Viking’s subsidiaries had approximately $79.8 million of indebtedness and other liabilities; Viking, excluding its subsidiaries, had no indebtedness for borrowed money.
In VK2735’s maintenance study, weight loss after the 21-week induction ranged approximately 16% to 19%, compared with approximately 0% for placebo. During the 12-week maintenance phase, every-other-week dosing maintained up to 97% of mean induction weight loss and monthly dosing up to 90%, compared with 61% for placebo in each comparison. Gastrointestinal-related adverse-event rates during maintenance were comparable to placebo.
Viking Therapeutics, Inc. is conducting a primary common-stock offering, with proceeds to the company after underwriting discounts and estimated offering expenses. The stock offering and a separate concurrent convertible-note offering are not contingent on each other. Viking intends to use stock-offering proceeds together with proceeds from the note offering, if completed, for continued work on VK2735 and VK3019, research and development, working capital, and general corporate purposes.
Viking Therapeutics, Inc. (VKTX) reported positive top-line results from a randomized, double-blind, placebo-controlled maintenance study of its dual GLP-1/GIP agonist VK2735 in adults with obesity. After a 21-week once-weekly induction phase, VK2735 produced mean weight loss of about 16–19% versus approximately 0% for placebo, with no plateau observed.
In the 12-week maintenance phase, subjects transitioning from weekly VK2735 to every-other-week dosing maintained up to 97% of prior weight loss, and those on monthly dosing maintained up to 90%, compared with 61% for placebo. An exploratory cohort continuing 17.5 mg weekly VK2735 achieved about 21.7% mean weight loss at Week 33 versus a 0.3% gain for placebo. Across maintenance regimens, rates of gastrointestinal adverse events and discontinuations were low and generally similar to placebo, which the company characterizes as an encouraging tolerability profile.
Dorothy Elizabeth Kelly-Gemmell, a director of Viking Therapeutics, Inc., received equity awards on August 1, 2026. She was granted a restricted stock unit award covering 6,333 shares of common stock, vesting in three equal annual installments, and stock options for 40,800 shares at an exercise price of $31.74 per share, also vesting one-third on each anniversary and expiring on August 1, 2036.
Viking Therapeutics, Inc. reports that Dorothy Elizabeth Kelly-Gemmell is a director of the company, and she is not an officer or a ten percent owner. This initial insider report lists no equity holdings or transactions, serving mainly to document her status as a director-level reporting person.
Viking Therapeutics, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer, from time to time, common stock, preferred stock, debt securities, warrants, rights, units and depositary shares. The filing also includes a dedicated sales agreement prospectus for an at-the-market offering of up to $500,000,000 of common stock through Stifel, Piper Sandler, Cantor Fitzgerald, Oppenheimer and Canaccord Genuity. Net proceeds from any sales are intended for working capital and general corporate purposes, potentially including acquisitions or business combinations.
As of June 30, 2026, Viking had 116,652,937 shares of common stock outstanding, with authorized capital of 300,000,000 common and 10,000,000 preferred shares. The company is a clinical-stage biopharmaceutical developer focused on metabolic and endocrine disorders, led by its GLP-1/GIP dual agonist VK2735 (injectable and oral), thyroid receptor beta agonist VK2809 for NASH/MASH, VK0214 for X-linked adrenoleukodystrophy, and other early-stage programs. The shelf enhances financing flexibility as these programs advance.